Minimal disease assessment in the treatment of @entity1 and adolescents with intermediate-risk (Stage III/IV) XXXX : a @entity1 's oncology group report.

@entity1 @entity66 @entity1334 @entity1892 @entity4145
@entity1 /adolescents with @entity1892 ( @entity1892 ) have an excellent prognosis but relapses still occur. While chromosomal aberrations and/or clonal immunoglobulin (Ig) gene rearrangements may indicate risk of failure, a more universal approach was developed to detect @entity66 ( @entity66 ). @entity1 /adolescents with intermediate-risk @entity1892 were treated with French-British-American/Lymphome Malins de Burkitt 96 ( @entity1334 modified chemotherapy and rituximab. Specimens from diagnosis, end of induction (EOI), and end of therapy (EOT) were assayed for @entity66 . Initial specimens were screened for IGHV family usage with primer pools followed by individual primers to identify @entity66 . Thirty-two diagnostic/staging specimens screened positive with primer pools and unique IGHV family primers were identified. Two @entity1 relapsed; first relapse (4 months from diagnosis) was @entity66 -positive at EOI, the second (36 months from diagnosis) was @entity66 -positive at EOT. At EOI, recurrent rates were similar between the @entity4145 -positive and @entity4145 -negative @entity1 (P = 0  40). At EOT, only 13/32 @entity1 had @entity4145 data available with one relapse in the @entity4145 -positive group and no recurrences in the @entity4145 -negative group (P = 0  077). The study demonstrated molecular-disseminated disease in which IgIGHV primer pools could be used to assess @entity66 . This feasibility study supports future investigations to assess the validity and significance of @entity66 screening in a larger cohort of @entity1 with intermediate-risk mature @entity1892 .
